免疫瘤学治疗药物的临床发展
Jianxin Wang1, Qi Chen1, Qiang Shan2
1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, 310003, China; The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310003, China.
免疫瘤学 (IO) 疗法利用免疫系统对抗癌症,免疫检查点抑制剂 (ICI) 迅速发展. 未来的研究重点是组合策略和生物标志物,以获得更广泛的应用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫瘤学 (IO) 是癌症治疗领域快速扩大的领域.
- IO剂利用宿主的免疫系统来准和消除瘤细胞.
- 自2011年以来,免疫检查点抑制剂 (ICI) 已成为批准的IO剂的主要类别.
研究的目的:
- 提供当前免疫瘤学药物及其应用的概述.
- 突出癌症免疫治疗的进展和局限性.
- 讨论免疫瘤学领域的未来方向.
主要方法:
- 对食品和药物管理局 (FDA) 批准的免疫瘤学 (IO) 剂的审查.
- 包括免疫检查点抑制剂 (ICI),CAR-T,BiTE,TCR,TIL,细胞因子,癌症疫苗和瘤病毒在内的IO疗法的分类.
- 对免疫疗法反应的癌症类型的分析和耐火性癌症的识别.
主要成果:
- 几类IO代理被批准,ICI是第二个最被批准的类别.
- 在治疗黑色素瘤,非小细胞肺癌 (NSCLC),细胞癌 (RCC) 和尿路细胞癌方面取得了重大进展.
- 某些癌症类型仍然对当前的免疫疗法方法具有抗性.
结论:
- 免疫瘤学在特定的癌症类型中取得了显著的成功.
- 未来的研究应该专注于新辅助剂/外科手术后应用,组合疗法和生物标志物开发以选择患者.
- 优化免疫疗法需要不断探索新的策略和预测标记.
相关概念视频
Tumor Immunotherapy
Preclinical Development: Overview
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


